Related references
Note: Only part of the references are listed.MX 2 is a novel regulator of cell cycle in melanoma cells
Marina Juraleviciute et al.
PIGMENT CELL & MELANOMA RESEARCH (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Potential New Therapeutic Approaches for Renal Cell Carcinoma
David C. Yang et al.
SEMINARS IN NEPHROLOGY (2020)
PTEN Is Involved in Sunitinib and Sorafenib Resistance in Renal Cell Carcinoma
Yohei Sekino et al.
ANTICANCER RESEARCH (2020)
Massively parallel reporter assays of melanoma risk variants identify MX2 as a gene promoting melanoma
Jiyeon Choi et al.
NATURE COMMUNICATIONS (2020)
PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy
Wenfeng Fang et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
Overexpression of human MX2 gene suppresses cell proliferation, migration, and invasion via ERK/P38/NF-κB pathway in glioblastoma cells
Huanyu Wang et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma
Shaw M. Akula et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2019)
Overexpression of FZD1 is Associated with a Good Prognosis and Resistance of Sunitinib in Clear Cell Renal Cell Carcinoma
Qiang Peng et al.
JOURNAL OF CANCER (2019)
Overexpression of miR-15b Promotes Resistance to Sunitinib in Renal Cell Carcinoma
Lu Lu et al.
JOURNAL OF CANCER (2019)
Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer
Kazuhiro Araki et al.
BREAST CANCER (2018)
Kinase-targeted cancer therapies: progress, challenges and future directions
Khushwant S. Bhullar et al.
MOLECULAR CANCER (2018)
Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway
Lihui Wang et al.
CELL DEATH & DISEASE (2018)
Mir-144-3p Promotes Cell Proliferation, Metastasis, Sunitinib Resistance in Clear Cell Renal Cell Carcinoma by Downregulating ARID1A
Wen Xiao et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2017)
EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming
Remi Adelaiye-Ogala et al.
CANCER RESEARCH (2017)
PTEN and PI3K/AKT in non-small-cell lung cancer
Cristina Perez-Ramirez et al.
PHARMACOGENOMICS (2015)
Mx GTPases: dynamin-like antiviral machines of innate immunity
Otto Haller et al.
TRENDS IN MICROBIOLOGY (2015)
Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma
Xian-De Liu et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Expression of TNF-α and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas
Shuji Mikami et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Sunitinib objective response in metastatic renal cell carcinoma: Analysis of 1059 patients treated on clinical trials
A. M. Molina et al.
EUROPEAN JOURNAL OF CANCER (2014)
Renal cell carcinoma
Eric Jonasch et al.
BMJ-BRITISH MEDICAL JOURNAL (2014)
Sunitinib, a tyrosine kinase inhibitor, induces cytochrome P450 1A1 gene in human breast cancer MCF7 cells through ligand-independent aryl hydrocarbon receptor activation
Zaid H. Maayah et al.
ARCHIVES OF TOXICOLOGY (2013)
Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation
Iori Sakai et al.
BJU INTERNATIONAL (2013)
Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection
Caroline Goujon et al.
NATURE (2013)
MX2 is an interferon-induced inhibitor of HIV-1 infection
Melissa Kane et al.
NATURE (2013)
Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (Review)
Sameh Hafsi et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
Dan Huang et al.
CANCER RESEARCH (2010)
Resistance to targeted therapy in renal-cell carcinoma
Brian I. Rini et al.
LANCET ONCOLOGY (2009)
Does Arterial Spin-labeling MR Imaging-measured Tumor Perfusion Correlate with Renal Cell Cancer Response to Antiangiogenic Therapy in a Mouse Model?
Rachel Schor-Bardach et al.
RADIOLOGY (2009)
Magnetic resonance imaging - Measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma
Cedric de Bazelaire et al.
CLINICAL CANCER RESEARCH (2008)
Modes of resistance to anti-angiogenic therapy
Gabriele Bergers et al.
NATURE REVIEWS CANCER (2008)
Anti-PIGF inhibits growth of VEGF(R)-Inhibitor-Resistant tumors without affecting healthy vessels
Christian Fischer et al.
CELL (2007)
Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance - Focus on tamoxifen, paclitaxel and imatinib metabolism
B Rochat
CLINICAL PHARMACOKINETICS (2005)
Share Paper
